NOVAVAX, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.88 USD | +98.66% |
|
+80.12% | +85.00% |
| May. 11 | Wall Street closes up ahead of inflation data | RE |
| May. 10 | News Highlights : Top Company News of the Day - Friday at 5 PM ET | DJ |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 93.33 | 4,079 | 10,817 | 883.9 | 570.2 | 1,238 | - | - |
| Enterprise Value (EV) 1 | 335.1 | 3,836 | 9,756 | -228.1 | 169.7 | 400.5 | 533.6 | 1,238 |
| P/E ratio | -0.72 x | -15.3 x | -6.1 x | -1.22 x | -0.89 x | -10.8 x | 22.5 x | -39.5 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 5 x | 8.58 x | 9.44 x | 0.45 x | 0.58 x | 1.41 x | 1.25 x | 1.27 x |
| EV / Revenue | 18 x | 8.07 x | 8.51 x | -0.12 x | 0.17 x | 0.46 x | 0.54 x | 1.27 x |
| EV / EBITDA | - | - | - | 0.37 x | -0.32 x | 1.77 x | -1.56 x | - |
| EV / FCF | -2.42 x | -39.5 x | 36.8 x | 0.45 x | -0.22 x | -5.85 x | -1.79 x | 3.36 x |
| FCF Yield | -41.3% | -2.53% | 2.72% | 221% | -452% | -17.1% | -55.9% | 29.7% |
| Price to Book | -0.69 x | 12.6 x | -30.9 x | -1.38 x | -0.93 x | -1.16 x | -1.23 x | - |
| Nbr of stocks (in thousands) | 23,449 | 36,578 | 75,608 | 85,979 | 118,790 | 139,402 | - | - |
| Reference price 2 | 3.980 | 111.5 | 143.1 | 10.28 | 4.800 | 8.880 | 8.880 | 8.880 |
| Announcement Date | 3/11/20 | 3/1/21 | 2/28/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 18.66 | 475.6 | 1,146 | 1,982 | 983.7 | 914.9 | 922.4 | 928.7 |
| EBITDA 1 | - | - | - | -615.7 | -525.3 | 226.2 | -342.4 | - |
| EBIT 1 | -129.6 | -416.7 | -1,687 | -644.7 | -566.5 | -65.57 | 52.65 | -30.5 |
| Operating Margin | -694.44% | -87.62% | -147.13% | -32.53% | -57.59% | -7.17% | 5.71% | -3.28% |
| Earnings before Tax (EBT) 1 | -132.7 | -418.3 | -1,715 | -653.6 | -543 | -93.79 | 53.3 | -30.2 |
| Net income 1 | -132.7 | -418.3 | -1,744 | -657.9 | -545.1 | -93.91 | 59.3 | -20.9 |
| Net margin | -711.04% | -87.94% | -152.12% | -33.2% | -55.41% | -10.26% | 6.43% | -2.25% |
| EPS 2 | -5.510 | -7.270 | -23.44 | -8.420 | -5.410 | -0.6296 | 0.7733 | -0.1400 |
| Free Cash Flow 1 | -138.5 | -97.16 | 265.5 | -505 | -767.7 | -68.5 | -298 | 368 |
| FCF margin | -742.04% | -20.43% | 23.16% | -25.48% | -78.05% | -7.49% | -32.31% | 39.63% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/11/20 | 3/1/21 | 2/28/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 222.2 | 704 | 185.9 | 734.6 | 357.4 | 80.95 | 424.4 | 187 | 291.3 | 93.86 | 102.2 | 82.68 | 602.9 |
| EBITDA | - | - | - | -118.8 | - | - | - | - | -172.8 | - | - | - | - |
| EBIT | -825 | 209.3 | -483 | -127.2 | -243.9 | -312.8 | 55.46 | -125.6 | -183.6 | -144.8 | - | -124.8 | - |
| Operating Margin | -371.27% | 29.73% | -259.76% | -17.31% | -68.24% | -386.37% | 13.07% | -67.19% | -63.01% | -154.31% | - | -150.95% | - |
| Earnings before Tax (EBT) 1 | -829.7 | 206.1 | -509.1 | -166.1 | -184.5 | -292.7 | 57.86 | -131.5 | -176.7 | -145.3 | -96.33 | -112.6 | 272.4 |
| Net income | -846.3 | 203.4 | -510.5 | -168.6 | -182.2 | -293.9 | 58.01 | -130.8 | -178.4 | -147.6 | - | -126.9 | - |
| Net margin | -380.87% | 28.89% | -274.57% | -22.95% | -50.99% | -363.07% | 13.67% | -69.94% | -61.23% | -157.21% | - | -153.49% | - |
| EPS 2 | -11.18 | 2.560 | -6.530 | -2.150 | -2.280 | -3.410 | 0.5800 | -1.260 | -1.440 | -1.050 | -0.7748 | -0.7761 | 1.753 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/28/22 | 5/9/22 | 8/8/22 | 11/8/22 | 2/28/23 | 5/9/23 | 8/8/23 | 11/9/23 | 2/28/24 | 5/10/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 242 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 243 | 1,061 | 1,112 | 400 | 837 | 704 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -138 | -97.2 | 265 | -505 | -768 | -68.5 | -298 | 368 |
| ROE (net income / shareholders' equity) | - | -190% | -1,266% | - | - | - | - | - |
| ROA (Net income/ Total Assets) | -74.4% | -47.7% | -83.8% | -27.2% | -26.9% | -9.5% | -22.3% | - |
| Assets 1 | 178.3 | 877.7 | 2,080 | 2,418 | 2,028 | 988.6 | -266.2 | - |
| Book Value Per Share 2 | -5.750 | 8.840 | -4.640 | -7.440 | -5.140 | -7.630 | -7.240 | - |
| Cash Flow per Share 2 | - | - | - | -5.320 | -7.090 | -1.170 | -1.360 | - |
| Capex 1 | 1.86 | 220 | 57.5 | 89.1 | 53.8 | 18.1 | 8 | 9.2 |
| Capex / Sales | 9.95% | 46.29% | 5.01% | 4.49% | 5.47% | 1.98% | 0.87% | 0.99% |
| Announcement Date | 3/11/20 | 3/1/21 | 2/28/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
8.88
USD
Average target price
18
USD
Spread / Average Target
+102.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +85.00% | 1.24B | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- NVAX Stock
- Financials Novavax, Inc.